The combination of PNPLA3 genotype, AST level, and fasting insulin level has been shown to be useful in predicting the histologic presence of NASH in a cohort of NAFLD patients[130]. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.